AbbVie (NYSE:ABBV) Issues Q3 2025 Earnings Guidance

AbbVie (NYSE:ABBV) issued an update on its third quarter 2025 earnings guidance on Friday morning. The company provided EPS guidance of 1.740-1.780 for the period, compared to the consensus EPS estimate of 3.260. The company issued revenue guidance of -. AbbVie also updated its FY 2025 guidance to 10.380-10.580 EPS.

Analysts Set New Price Targets

Several research firms have recently commented on ABBV. Daiwa America upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 7th. Piper Sandler started coverage on shares of AbbVie in a research note on Tuesday, August 12th. They set an “overweight” rating and a $231.00 price objective for the company. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Saturday, September 27th. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. Finally, Raymond James Financial restated an “outperform” rating on shares of AbbVie in a research report on Monday, August 25th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $228.22.

AbbVie Stock Down 1.1%

ABBV opened at $234.07 on Friday. AbbVie has a twelve month low of $163.81 and a twelve month high of $244.81. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a 50-day moving average price of $210.77 and a 200 day moving average price of $196.01. The company has a market cap of $413.49 billion, a PE ratio of 111.46, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.42 billion for the quarter, compared to analyst estimates of $14.93 billion. During the same quarter last year, the company earned $2.65 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis. Sell-side analysts expect that AbbVie will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a dividend yield of 2.8%. AbbVie’s dividend payout ratio is 312.38%.

Insider Buying and Selling

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares of the company’s stock, valued at $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ABBV. Headlands Technologies LLC boosted its holdings in shares of AbbVie by 234.0% in the second quarter. Headlands Technologies LLC now owns 8,812 shares of the company’s stock valued at $1,636,000 after acquiring an additional 6,174 shares in the last quarter. Nikulski Financial Inc. boosted its holdings in shares of AbbVie by 2.0% in the second quarter. Nikulski Financial Inc. now owns 39,671 shares of the company’s stock valued at $7,364,000 after acquiring an additional 775 shares in the last quarter. Security National Bank of Sioux City Iowa IA boosted its holdings in shares of AbbVie by 14.5% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 15,337 shares of the company’s stock valued at $2,847,000 after acquiring an additional 1,948 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in shares of AbbVie in the second quarter valued at about $969,000. Finally, Brooks Moore & Associates Inc. boosted its holdings in shares of AbbVie by 0.5% in the second quarter. Brooks Moore & Associates Inc. now owns 28,492 shares of the company’s stock valued at $5,386,000 after acquiring an additional 149 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.